These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Experimental hypoxia does not influence gene expression and protein synthesis of Eph receptors and ephrin ligands in human melanoma cells in vitro. Reissenweber B; Mosch B; Pietzsch J Melanoma Res; 2013 Apr; 23(2):85-95. PubMed ID: 23358429 [TBL] [Abstract][Full Text] [Related]
8. The EphB4 receptor-tyrosine kinase promotes the migration of melanoma cells through Rho-mediated actin cytoskeleton reorganization. Yang NY; Pasquale EB; Owen LB; Ethell IM J Biol Chem; 2006 Oct; 281(43):32574-86. PubMed ID: 16950769 [TBL] [Abstract][Full Text] [Related]
9. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Noren NK; Lu M; Freeman AL; Koolpe M; Pasquale EB Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5583-8. PubMed ID: 15067119 [TBL] [Abstract][Full Text] [Related]
10. The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis. Martiny-Baron G; Holzer P; Billy E; Schnell C; Brueggen J; Ferretti M; Schmiedeberg N; Wood JM; Furet P; Imbach P Angiogenesis; 2010 Sep; 13(3):259-67. PubMed ID: 20803239 [TBL] [Abstract][Full Text] [Related]
11. EphB4 overexpression in B16 melanoma cells affects arterial-venous patterning in tumor angiogenesis. Huang X; Yamada Y; Kidoya H; Naito H; Nagahama Y; Kong L; Katoh SY; Li WL; Ueno M; Takakura N Cancer Res; 2007 Oct; 67(20):9800-8. PubMed ID: 17942910 [TBL] [Abstract][Full Text] [Related]
12. Dual-modality micro-positron emission tomography/computed tomography and near-infrared fluorescence imaging of EphB4 in orthotopic glioblastoma xenograft models. Huang M; Xiong C; Lu W; Zhang R; Zhou M; Huang Q; Weinberg J; Li C Mol Imaging Biol; 2014 Feb; 16(1):74-84. PubMed ID: 23918654 [TBL] [Abstract][Full Text] [Related]
13. In vivo small-animal PET/CT of EphB4 receptors using 64Cu-labeled peptide. Xiong C; Huang M; Zhang R; Song S; Lu W; Flores L; Gelovani J; Li C J Nucl Med; 2011 Feb; 52(2):241-8. PubMed ID: 21233177 [TBL] [Abstract][Full Text] [Related]
14. Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions. Xiong C; Wen Y; Zhao J; Yin D; Xu L; Chelariu-Raicu A; Yao C; Leng X; Liu J; Chaudhari RR; Zhang S; Sood AK; Li C Sci Rep; 2020 Jan; 10(1):520. PubMed ID: 31949258 [TBL] [Abstract][Full Text] [Related]
15. Ephrin-B2-EphB4 communication mediates tumor-endothelial cell interactions during hematogenous spread to spinal bone in a melanoma metastasis model. Broggini T; Piffko A; Hoffmann CJ; Ghori A; Harms C; Adams RH; Vajkoczy P; Czabanka M Oncogene; 2020 Nov; 39(47):7063-7075. PubMed ID: 32989254 [TBL] [Abstract][Full Text] [Related]
16. EphB4 inhibitor overcome the acquired resistance to cisplatin in melanomas xenograft model. Yang X; Yang Y; Tang S; Tang H; Yang G; Xu Q; Wu J J Pharmacol Sci; 2015 Sep; 129(1):65-71. PubMed ID: 26390965 [TBL] [Abstract][Full Text] [Related]
17. Targeting receptor tyrosine kinase EphB4 in cancer therapy. Chen Y; Zhang H; Zhang Y Semin Cancer Biol; 2019 Jun; 56():37-46. PubMed ID: 28993206 [TBL] [Abstract][Full Text] [Related]